<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332566</url>
  </required_header>
  <id_info>
    <org_study_id>106602</org_study_id>
    <nct_id>NCT00332566</nct_id>
  </id_info>
  <brief_title>Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib</brief_title>
  <official_title>Immunogenicity, Reactogenicity &amp; Safety of a Booster Dose of GSK Biologicals' DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals' DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This booster study will assess the immunogenicity, reactogenicity and safety of a booster&#xD;
      dose of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine versus DTPw-HBV/Hib vaccine, in healthy&#xD;
      children, 18 to 24 months of age, who received the same vaccine for primary vaccination.&#xD;
      Prior to the booster dose, this study will also assess the persistence of antibodies to the&#xD;
      vaccine antigen components administered in the primary vaccination course. The Protocol&#xD;
      Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-polyribosyl-ribitol-phosphate (PRP) antibody concentration</measure>
    <time_frame>One month after the booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-hepatitis B surface antigen (HBs) antibody concentration</measure>
    <time_frame>One month after the booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-diphtheria antibody concentration</measure>
    <time_frame>One month after the booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tetanus antibody concentration</measure>
    <time_frame>One month after the booster dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Bordetella pertussis (BPT) antibody concentration</measure>
    <time_frame>One month after the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP antibody concentration</measure>
    <time_frame>Prior to the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs antibody concentration</measure>
    <time_frame>Prior to the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diphtheria antibody concentration</measure>
    <time_frame>Prior to the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tetanus antibody concentration</measure>
    <time_frame>Prior to the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-BPT antibody concentration</measure>
    <time_frame>Prior to the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited symptoms</measure>
    <time_frame>During the 4-day follow-up period after the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms</measure>
    <time_frame>During the 31-day follow-up period after the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>During the entire study period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Whole Cell Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Diphtheria</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPw-HBV/Hib Kft vaccine GSK323527A</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix™-HepB/Hiberix™</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who the investigator believes that their parents/guardians can and will&#xD;
             comply with the requirements of the protocol should be enrolled in the study.&#xD;
&#xD;
          -  A male or female toddler, 18 to 24 months of age at the time of booster vaccination,&#xD;
             who completed the three-dose primary vaccination course in the 101223 study.&#xD;
&#xD;
          -  Written informed consent obtained from the parent or guardian of the subject.&#xD;
&#xD;
          -  Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccines within 30 days preceding the booster dose of study vaccine, or planned&#xD;
             use during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs within six months prior to the booster vaccine dose.&#xD;
&#xD;
          -  Planned administration/ administration of a vaccine not foreseen by the study protocol&#xD;
             during the period starting from 30 days before and ending 30 days after administration&#xD;
             of the booster vaccine dose, with the exception of oral polio vaccine (OPV).&#xD;
&#xD;
          -  Previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis B and&#xD;
             Hib disease since the conclusion visit of the 101223 study.&#xD;
&#xD;
          -  History of diphtheria, tetanus, pertussis, hepatitis B and Hib disease.&#xD;
&#xD;
          -  Known exposure to diphtheria, tetanus, pertussis, hepatitis B and Hib disease since&#xD;
             the conclusion visit of the 101223 study.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine(s).&#xD;
&#xD;
          -  Major congenital defects or serious chronic illness.&#xD;
&#xD;
          -  History of any neurologic disorders or seizures.&#xD;
&#xD;
          -  Acute disease at the time of enrolment.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products during the study period.&#xD;
&#xD;
          -  Other conditions which in the opinion of the investigator may potentially interfere&#xD;
             with interpretation of study outcomes.&#xD;
&#xD;
          -  One of the following adverse events that constitute absolute contraindications to&#xD;
             further administration of DTP vaccine, having occurred after previous administration&#xD;
             of DTPw vaccine.&#xD;
&#xD;
               -  Known hypersensitivity to any component of the vaccine, or having shown signs of&#xD;
                  hypersensitivity after previous administration of diphtheria, tetanus, pertussis&#xD;
                  or HB vaccines.&#xD;
&#xD;
               -  Encephalopathy&#xD;
&#xD;
               -  Axillary temperature of &gt;= 40 °C/ rectal temperature &gt;= 40.5 °C within 48 hours&#xD;
                  of vaccination.&#xD;
&#xD;
               -  Collapse or shock-like state within 48 hours of vaccination.&#xD;
&#xD;
               -  Persistent, inconsolable crying lasting &gt;= 3 hours occurring within 48 hours of&#xD;
                  vaccination.&#xD;
&#xD;
               -  Seizures with or without fever occurring within 3 days of vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leon</city>
        <country>Nicaragua</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Nicaragua</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>May 31, 2006</study_first_submitted>
  <study_first_submitted_qc>May 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2006</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>106602</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106602</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106602</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106602</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106602</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106602</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

